First Wave Biopharma, Inc. (FWBI) SEC Filing 8-K Material Event for the period ending Monday, May 16, 2022

First Wave Biopharma, Inc.

CIK: 1604191 Ticker: FWBI

View differences made from one to another to evaluate First Wave Biopharma, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by First Wave Biopharma, Inc..


Assess how First Wave Biopharma, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

First Wave Biopharma, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Ticker: FWBI
CIK: 1604191
Form Type: 8-K Corporate News
Accession Number: 0001140361-22-019437
Submitted to the SEC: Mon May 16 2022 5:27:49 PM EST
Accepted by the SEC: Mon May 16 2022
Period: Monday, May 16, 2022
Industry: Pharmaceutical Preparations
  1. Listing Status
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: